Brief: Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
07/05/2024 14:04
May 7 (Reuters) - Sagimet Biosciences Inc SGMT.O :
* SAGIMET ANNOUNCES ORAL PRESENTATION OF DATA FROM THE PHASE
2B
FASCINATE-2 STUDY OF DENIFANSTAT IN MASH AT EASL INTERNATIONAL
LIVER CONGRESS 2024
Source text for Eikon: ID:nGNX64wqkJ
Further company coverage: SGMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage